Israel

Immunity Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Immunity Pharma Announces Promising Interim Results of its Phase 1/2a Study with IPL344 in ALS

Lead Product(s): IPL344

Therapeutic Area: Neurology Product Name: IPL344

Highest Development Status: Phase II Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 10, 2020

Details:

In this early stage clinical trial, disease progression rate during IPL344 treatment was about 50% slower than expected without treatment, in both functional and respiratory endpoints. The drug also demonstrated a very favorable safety and tolerability profile.

Prothena

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results

Lead Product(s): Prasinezumab

Therapeutic Area: Neurology Product Name: RO7046015

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 03, 2020

Details:

Company will present Part 1 of the Phase 2 PASADENA study of prasinezumab in early Parkinson’s disease. Results from Part 1 of the Phase 2 PASADENA study of prasinezumab were selected as an oral Top Abstract presentation at the upcoming Virtual 2020 MDS Congress.

PainReform

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Israeli Pain Relief Biotech PainReform Files for a $25 million US IPO

Lead Product(s): ROPIVACAINE HYDROCHLORIDE

Therapeutic Area: Neurology Product Name: PRF-110

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Maxim Group LLC

Deal Size: $25.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering June 30, 2020

Details:

The company's lead candidate and first product, PRF-110, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. Company plans to initiate two Phase 3 trials for PRF-110 soon after the closing of this offering.

Prothena

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Prothena Corporation Provides Update on Its Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease

Lead Product(s): Prasinezumab

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 22, 2020

Details:

The study did not achieve the primary goal, but did show signs of efficacy. Roche has begun further clinical development preparation and is reviewing the results from PASADENA Study Part 1.

Prothena

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Baseline Data from Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson's Disease to be Presented at AAT-AD/PD

Lead Product(s): Prasinezumab

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 31, 2020

Details:

PASADENA is a two-part Phase 2 clinical study in patients with early Parkinson’s disease that is being conducted by Roche.

NeuroSense Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

NeuroSense Receives Orphan Drug Designation for Amyotrophic

Lead Product(s): Ciprofloxacin,Celecoxib

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 06, 2020

Details:

The clinical trials initiated in the United States and in Israel will evaluate safety, tolerability and efficacy of PrimeC, NeuroSense's product for ALS patients.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Immunity Pharma

Immunity Pharma Announces Promising Interim Results of its Phase 1/2a Study with IPL344 in ALS

Prothena

Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results

PainReform

Israeli Pain Relief Biotech PainReform Files for a $25 million US IPO

Prothena

Prothena Corporation Provides Update on Its Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease

Prothena

Baseline Data from Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson's Disease to be Presented at AAT-AD/PD

NeuroSense Therapeutics

NeuroSense Receives Orphan Drug Designation for Amyotrophic